No Data
CVRx Announces New Publication Reinforcing the Long-term Quality of Life Benefits of Barostim
CVRx Initiated at Overweight by Cantor Fitzgerald
Cantor Fitzgerald Initiates CVRx Inc(CVRX.US) With Buy Rating, Announces Target Price $14
Express News | CVRx Announces Appointment of Two New Board Members
CCORF Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $15
CVRx Analyst Ratings